INS and type 1 diabetes mellitus: In the autoimmune disease, type 1 diabetes (T1D), the progressive loss of functional β-cell mass precipitates clinical onset of hyperglycemia and requires life-long insulin replacement therapy, but dysregulation of glucagon secretion is also present at an early stage and represents a significant impediment to optimal disease management1–3.